Clinical trial
Scleroderma: Cyclophosphamide or Transplantation
NCT00114530 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00114530 |
|---|---|
| Title | Scleroderma: Cyclophosphamide or Transplantation |
| Official title | A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01) |
| Acronym | SCOT |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Rho Federal Systems Division, Inc. Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Scleroderma, Systemic, Sclerosis, Autoimmune Disease |
| Intervention type | Biological, Drug |
| Interventions | mHSCT, cyclophosphamide |
| Enrollment | 75 |
| Start date | Jun 1, 2005 |
| Primary completion | Apr 1, 2016 |
| Completion | Apr 1, 2016 |
| First posted | Jun 16, 2005 |
| Last update posted | Apr 12, 2023 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: